FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

José Moltó

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Procedures

Living Beings

HIV-1

Concepts & Ideas

Co-author Network

Publications

TOP 3
José Moltó; Eugenia Negredo; Marta Valle; Samandhy Cedeño; Cristina Miranda; Bonaventura Clotet
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Javier A Estévez; Maria A Mangues; José Moltó; Montserrat Puntes; Laura Tuneu; Rosa Antonijoan; Manuel J Barbanoj; Samandhy Cedeño; Bonaventura Clotet; Pere Domingo; Marta Valle
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
José Moltó; Eugenia Negredo; Marta Valle; Samandhy Cedeño; Cristina Miranda; Bonaventura Clotet
Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of José Moltó (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: José Moltó; Eugenia Negredo; Marta Valle; Samandhy Cedeño; Cristina Miranda; Bonaventura Clotet
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Antimicrobial agents and chemotherapy 2012;56(10):5328-31.
2012: Javier A Estévez; Maria A Mangues; José Moltó; Montserrat Puntes; Laura Tuneu; Rosa Antonijoan; Manuel J Barbanoj; Samandhy Cedeño; Bonaventura Clotet; Pere Domingo; Marta Valle
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
The Journal of antimicrobial chemotherapy 2012;67(8):2013-9.
2012: José Moltó; Eugenia Negredo; Marta Valle; Samandhy Cedeño; Cristina Miranda; Bonaventura Clotet
Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients.
Antimicrobial agents and chemotherapy 2012;56(6):2837-41.
2012: José Moltó; Marta Valle; Antonia Andreu; Xavier Bonafont; Sara Malo; Cristina Miranda; Bonaventura Clotet
[Use of herbal remedies among HIV-infected patients: patterns and correlates].
Medicina clínica 2012;138(3):93-8.
2012: José R Santos; Isabel Bravo; Bonaventura Clotet; Josep M Llibre; José Moltó; Eugenia Negredo; Arelly Ornelas; Roger Paredes
Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
PloS one 2012;7(5):e37442.
2011: Cristina Tural; Miguel Ángel von Wichmann; Ana Moreno Zamora; Núria Pérez Alvarez; Bonaventura Clotet; Juan González; Montserrat Laguno; José Moltó; Arelly Ornelas; Roger Paredes; Matilde Sánchez; Ricard Solà; Maria Jesús Téllez
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Antiviral therapy 2011;16(6):833-41.
2011: José Moltó; Marta Valle; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Manuel José Barbanoj; Bonaventura Clotet
Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Antimicrobial agents and chemotherapy 2011;55(1):326-30.
2011: José Moltó; Marta Valle; David Back; Samandhy Cedeño; Victoria Watson; Neill Liptrott; Deirdre Egan; Cristina Miranda; Manuel J Barbanoj; Bonaventura Clotet
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Antimicrobial agents and chemotherapy 2011;55(1):72-5.
2010: Josep M Llibre; Antonio Antela; José Ramón Arribas; Pere Domingo; Josep M Gatell; José López Aldeguer; Fernando Lozano; Celia Miralles; José Moltó; Santiago Moreno; Enrique Ortega; Melcior Riera; Antonio Rivero; Concepción Villalonga; Bonaventura Clotet
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].
Enfermedades infecciosas y microbiología clínica 2010;28(9):615-20.
2010: José Moltó; Marta Valle; José Ramón Santos; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Mercedes Yritia; Sebastián Videla; Bonaventura Clotet
Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
AIDS research and human retroviruses 2010;26(11):1191-6.
2010: José Moltó; José Sanz-Moreno; Marta Valle; Samandhy Cedeño; Jordi Bonal; Hanane Bouarich; Bonaventura Clotet
Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.
Antimicrobial agents and chemotherapy 2010;54(7):3047-8.
2010: Jose Munoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugenia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Journal of neurovirology 2010;16(3):208-18.
2010: Eugenia Negredo; Marta Massanella; Jordi Puig; Núria Pérez-Alvarez; José Miguel Gallego-Escuredo; Joan Villarroya; Francesc Villarroya; José Moltó; José Ramón Santos; Bonaventura Clotet; Julià Blanco
Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(9):1300-8.
2010: José Moltó; Elisabet Deig; Marta Valle; Josep Maria Llibre; Cristina Miranda; Samandhy Cedeño; Silvia Valero; Eugenia Negredo; Bonaventura Clotet
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Therapeutic drug monitoring 2010;32(1):93-6.
2010: José Moltó; Marta Valle; José Ramón Santos; Beatriz Mothe; Cristina Miranda; Samandhy Cedeño; Eugenia Negredo; Mercedes Yritia; Sebastián Videla; Manuel José Barbanoj; Bonaventura Clotet
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Antiviral therapy 2010;15(2):219-25.
2009: José R Santos; Josep M Llibre; Elena Ferrer; Pere Domingo; Arkaitz Imaz; José Moltó; Raquel Martin-Iguacel; Carme Caum; Daniel Podzamczer; Bonaventura Clotet
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
HIV clinical trials 2009;10(6):432-8.
2009: José Ramón Santos; José Moltó; Josep M Llibre; Nuria Pérez; Cristina Miranda; Bonaventura Clotet
Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
HIV clinical trials 2009;10(3):129-34.
2009: José Moltó; Josep Maria Llibre; Esteban Ribera; Carlos Mínguez; Jesús Sánchez del Río; Enric Pedrol; Gabriel Vallecillo; Samandhy Cedeño; Marta Valle; Cristina Miranda; Eugenia Negredo; Bonaventura Clotet
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
The Journal of antimicrobial chemotherapy 2009;63(5):992-7.
2009: Jose Munoz-Moreno; Carmina R Fumaz; Maria J Ferrer; Marian González-García; José Moltó; Eugenia Negredo; Bonaventura Clotet
Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
AIDS reviews 2009;11(2):103-9.
2008: José Moltó; José R Santos; Nuria Pérez-Alvarez; Samandhy Cedeño; Cristina Miranda; Saye Khoo; Laura Else; Josep Maria Llibre; Marta Valle; Bonaventura Clotet
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2008;52(11):3928-32.
2008: J M Llibre; J R Santos; T Puig; José Moltó; Lidia Ruiz; Roger Paredes; Bonaventura Clotet
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
The Journal of antimicrobial chemotherapy 2008;62(5):909-13.
2008: Jose Munoz-Moreno; Carmina R Fumaz; Maria J Ferrer; Anna Prats; Eugenia Negredo; Maite Garolera; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Bonaventura Clotet
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.
AIDS research and human retroviruses 2008;24(10):1301-7.
2008: José Moltó; Marta Valle; Cristina Miranda; Samandhy Cedeño; José Miranda; José Ramón Santos; Eugenia Negredo; Josep Vilaró; Joan Costa; Bonaventura Clotet
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
The Journal of antimicrobial chemotherapy 2008;62(4):784-92.
2007: José Moltó; José Ramón Santos; Marta Valle; Cristina Miranda; José Miranda; Asunción Blanco; Eugenia Negredo; Bonaventura Clotet
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Therapeutic drug monitoring 2007;29(5):648-51.
2007: José Moltó; José Ramón Santos; Eugenia Negredo; Cristina Miranda; Sebastián Videla; Bonaventura Clotet
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
The Journal of antimicrobial chemotherapy 2007;60(2):436-9.
2007: José Moltó; Asunción Blanco; Cristina Miranda; José Miranda; Jordi Puig; Marta Valle; Meritxell DelaVarga; Carmina R Fumaz; Manel J Barbanoj; Bonaventura Clotet
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
British journal of clinical pharmacology 2007;63(6):715-21.
2007: José Moltó; Marta Valle; Asunción Blanco; Eugenia Negredo; Meritxell DelaVarga; Cristina Miranda; José Miranda; Pere Domingo; Josep Vilaró; Cristina Tural; Joan Costa; Manel J Barbanoj; Bonaventura Clotet
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
Clinical pharmacokinetics 2007;46(1):85-92.
2006: Eugenia Negredo; José Moltó; Jordi Puig; Denise Cinquegrana; Anna Bonjoch; Núria Pérez-Alvarez; Raquel López-Blázquez; Asunción Blanco; Bonaventura Clotet; Celestino Rey-Joly
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
AIDS (London, England) 2006;20(17):2159-64.
2006: José Moltó; Asunción Blanco; Cristina Miranda; José Miranda; Jordi Puig; Marta Valle; Meritxell DelaVarga; Carmina R Fumaz; Manel J Barbanoj; Bonaventura Clotet
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
British journal of clinical pharmacology 2006;62(5):560-6.
2006: Eugenia Negredo; Bonaventura Clotet; Jordi Puig; Núria Pérez-Alvarez; Lidia Ruiz; Joan Romeu; José Moltó; Celestino Rey-Joly; Julià Blanco
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
AIDS (London, England) 2006;20(4):619-21.
2006: José Moltó; Lidia Ruiz; Marta Valle; Javier Martinez-Picado; Anna Bonjoch; Isabel Bravo; Eugenia Negredo; Gabrielle M Heilek-Sneider; Bonaventura Clotet
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Antiviral therapy 2006;11(1):47-51.
2005: Alain Pruvost; Eugenia Negredo; Henri BENECH; Frédéric Theodoro; Jordi Puig; Eulàlia Grau; Elisabet García; José Moltó; Jacques Grassi; Bonaventura Clotet
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2005;49(5):1907-14.
2005: Carmina R Fumaz; Jose Munoz-Moreno; José Moltó; Eugenia Negredo; Maria José Ferrer; Guillem Sirera; Núria Pérez-Alvarez; Guadalupe Gómez; David Burger; Bonaventura Clotet
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Journal of acquired immune deficiency syndromes (1999) 2005;38(5):560-5.
2005: Eugenia Negredo; José Moltó; David Burger; Helene Côté; Oscar Miró; Josep Ribalta; Eva Martínez; Jordi Puig; Lidia Ruiz; Juliana Salazar; Sònia López; Julio Montaner; Celestino Rey-Joly; Bonaventura Clotet
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Journal of acquired immune deficiency syndromes (1999) 2005;38(1):47-52.
2004: José Moltó; Lidia Ruiz; Joan Romeu; Javier Martínez-Picado; Eugenia Negredo; Cristina Tural; Guillem Sirera; Bonaventura Clotet
Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
AIDS research and human retroviruses 2004;20(12):1283-8.
2004: Eugenia Negredo; José Moltó; Jose Munoz-Moreno; Enric Pedrol; Esteban Ribera; Pompeyo E. Viciana; M José Galindos; Celia Miralles; David Burger; Carmina Rodriguez Fumaz; Jordi Puig; Silvia Gel; Eva Rodríguez; Sebastián Videla; Lidia Ruiz; Bonaventura Clotet
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Antiviral therapy 2004;9(3):335-42.
2004: Eugenia Negredo; José Moltó; David Burger; Pompeyo E. Viciana; Esteban Ribera; Roger Paredes; Manel Juan; Lidia Ruiz; Jordi Puig; Alain Pruvost; Jacques Grassi; Elisabeth Masmitjà; Bonaventura Clotet
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
AIDS (London, England) 2004;18(3):459-63.